

September 27, 2022

Dear Valued Customer,

Fresenius Kabi is committed to delivering high quality Diprivan® (Propofol) Injectable Emulsion, USP to the U.S. market, and we have implemented several strategies to maintain reliable and consistent supply. It has been brought to our attention that there have been rumors of low inventory, and we want to assure you that our Diprivan inventory is healthy across our entire supply chain, and we have more than enough Diprivan product to meet our wholesaler and end-customer demand. There should be no need for allocations of Diprivan anywhere along the supply chain.

For years we have held several months of U.S. Diprivan demand¹ within our distribution network and have increased our safety stock even further across all product presentations during the COVID-19 pandemic. In both 2020 and 2021, we provided more than 60 million units of propofol to U.S. customers, significantly increasing production to meet the unprecedented demand for 100 mL propofol¹. We maintain this level of production through today. We know you have a choice for your propofol supply and are honored that you entrust us with your propofol needs.

Thank you for choosing Diprivan and for continuing to make it the number one propofol product in the U.S. market.¹ If you have any questions or feedback, please do not hesitate to contact me or your local sales representative directly. Our customer service team is also available and can be reached at 888.386.1300.

Best regards,



Angie Lindsey
Vice President, Marketing

angie.lindsey@fresenius-kabi.com
www.fresenius-kabi.us

¹Fresenius Kabi data on file